Preoperatively Treated Diffuse-Type Gastric Adenocarcinoma: Glucose vs. Other Energy Sources Substantially Influence Prognosis and Therapy Response
Autor: | Catherine E Devine, Brian D. Badgwell, Yang Lu, Allison Trail, Jane E. Rogers, Prajnan Das, Rebecca E Waters, Madhavi Patnana, Ahmed Abdelhakeem, Xuemei Wang, Jaffer A. Ajani, Naruhiko Ikoma, Jeannelyn S. Estrella, Mariela A. Blum Murphy |
---|---|
Rok vydání: | 2021 |
Předmět: |
Cancer Research
medicine.medical_specialty FDG chemical and pharmacologic phenomena Standardized uptake value lcsh:RC254-282 Gastroenterology Article 03 medical and health sciences Gastric adenocarcinoma 0302 clinical medicine Internal medicine medicine diffuse gastric cancer Diffuse type Preoperative chemotherapy Avidity Intestinal type business.industry lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens PET Therapy response Oncology 030220 oncology & carcinogenesis 030211 gastroenterology & hepatology prognosis business Energy source |
Zdroj: | Cancers, Vol 13, Iss 420, p 420 (2021) Cancers Volume 13 Issue 3 |
ISSN: | 2072-6694 |
Popis: | Diffuse type of gastric adenocarcinoma (dGAC) generally confers a poor prognosis compared to intestinal type. Some dGACs are not avid on fluorine-18 fluoro-2-deoxy-D-glucose PET (FDG-PET) while others seem to consume glucose avidly. We analyzed the outcomes based on the avidity (high with standardized uptake value (SUV) > 3.5 or low with SUV &le 3.5) of the primary on baseline FDG-PET. We retrospectively selected 111 localized dGAC patients who had baseline FDG-PET (all were treated with preoperative chemotherapy and chemoradiation). FDG-PET avidity was compared with overall survival (OS) and response to therapy. The mean age was 59.4 years and with many females (47.7%). The high-SUV group (58 (52.3%) patients) and the low-SUV group (53 (47.7%) patients) were equally divided. While the median OS for all patients was 49.5 months (95% CI: 38.5&ndash 98.8 months), it was 98.0 months (95% CI: 49.5&ndash NE months) for the low-SUV group and 36.0 months for the high-SUV (p = 0.003). While the median DFS for all patients was 38.2 months (95% CI: 27.7&ndash 97.6 months), it was 98.0 (95% CI: 36.9&ndash NE months) months for the low-SUV group was and only 27.0 months (95% CI: 15.2&ndash 63.2 months) for the high-SUV group (p = 0.005). Clinical responses before surgery were more common in the low-SUV group but overall we observed only 4 pathologic complete responses in 111 patients. Our unique data suggest that if dGACs used glucose as an energy source then the prognosis was very poor while non-glucose sources improved prognosis. Multi-platform (including metabolomics) profiling of dGACs would yield useful biologic understanding. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |